LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 283

Search options

  1. Book: Pan cancer integrative molecular portrait towards a new paradigm in precision medicine

    Le Tourneau, Christophe / Kamal, Maud

    2015  

    Title variant Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine
    Author's details Christophe Le Tourneau ; Maud Kamal ed
    Keywords Cancer personalized medicine ; High throughput screening techniques ; Pathology ; Bioinformatics ; Predictive biomarkers
    Language English
    Size X, 144 S. : Ill., graph. Darst., 235 mm x 155 mm, 0 g
    Publisher Springer
    Publishing place Cham u.a.
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT018770576
    ISBN 978-3-319-22188-5 ; 978-3-319-22189-2 ; 3-319-22188-4 ; 3-319-22189-2
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2015 A 3373 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The potential roles of antibody-drug conjugates in head and neck squamous cell carcinoma.

    Filippini, Daria Maria / Le Tourneau, Christophe

    Current opinion in oncology

    2024  Volume 36, Issue 3, Page(s) 147–154

    Abstract: Purpose of review: To summarize the actual antibody-drug conjugates (ADCs) tested for patients with advanced head and neck squamous cell carcinoma (HNSCC), outlining the results of safety and efficacy through published clinical trials.: Recent ... ...

    Abstract Purpose of review: To summarize the actual antibody-drug conjugates (ADCs) tested for patients with advanced head and neck squamous cell carcinoma (HNSCC), outlining the results of safety and efficacy through published clinical trials.
    Recent findings: ADCs combine the specificity of mAbs with the cytotoxic drug (known as payload) via a chemical linker and it is designed to selectively deliver the ultratoxic payload directly to the target cancer cells. To date, various ADCs have been investigated in multiple solid malignancies and others are in clinical development. In this study, we provide an overview of the structure and biology of ADC and we review recent clinical experience with the ADC in patients with advanced HNSCC, followed by a brief discussion of the evolvement of ADC conception, drug resistance and future perspectives.
    Summary: ADC strategy is emerging as a potential active treatment in previously treated patients with advanced HNSCC. However, the recent improvement in the bioengineering of ADC and a better comprehension of sequencing and association strategies could provide more benefit to HNSCC patients in need of innovative therapy.
    MeSH term(s) Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Antibodies, Monoclonal ; Immunoconjugates/therapeutic use ; Head and Neck Neoplasms/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Immunoconjugates
    Language English
    Publishing date 2024-02-07
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000001022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Premiers pas de l’intelligence artificielle pour guider les thérapies en oncologie.

    Le Tourneau, Christophe / Bièche, Ivan / Kamal, Maud

    Medecine sciences : M/S

    2022  Volume 38, Issue 1, Page(s) 21–22

    Title translation Starting to integrate artificial intelligence for treatment decisions in oncology.
    MeSH term(s) Algorithms ; Artificial Intelligence ; Humans ; Medical Oncology
    Language French
    Publishing date 2022-01-21
    Publishing country France
    Document type News
    ZDB-ID 632733-3
    ISSN 1958-5381 ; 0767-0974
    ISSN (online) 1958-5381
    ISSN 0767-0974
    DOI 10.1051/medsci/2021235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2872: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma.

    Marret, Grégoire / Borcoman, Edith / Le Tourneau, Christophe

    Current opinion in oncology

    2023  Volume 35, Issue 3, Page(s) 158–165

    Abstract: Purpose of review: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous cell carcinoma (HNSCC), and discuss their challenges.: Recent findings: Limited treatment options exist in HNSCC. Cetuximab, an ... ...

    Abstract Purpose of review: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous cell carcinoma (HNSCC), and discuss their challenges.
    Recent findings: Limited treatment options exist in HNSCC. Cetuximab, an mAb targeting epidermal growth factor receptor, and the PD-1 inhibitors nivolumab and pembrolizumab, are the only drugs that improved overall survival in the recurrent and/or metastatic setting. Both cetuximab and nivolumab improve overall survival by less than 3 months, potentially because of the lack of predictive biomarkers. The only validated predictive biomarker to date is protein ligand PD-L1 expression that predicts the efficacy of pembrolizumab in first-line, nonplatinum refractory recurrent and/or metastatic HNSCC. The identification of biomarkers of efficacy of new drugs is key to avoid administering toxic drugs to patients who will not benefit from them, and to expect increased drug efficacy in the biomarker-positive group of patients. One way of identifying such biomarkers are the window-of-opportunity trials in which drugs are given for a short period of time before the definitive treatment, with the aim to collect samples for translational research. These trials differ from neoadjuvant strategies where efficacy is the primary endpoint.
    Summary: We show that these trials were safe and successful in identifying biomarkers.
    MeSH term(s) Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Nivolumab/therapeutic use ; Cetuximab ; Head and Neck Neoplasms/drug therapy ; Biomarkers ; Neoplasm Recurrence, Local/drug therapy
    Chemical Substances Nivolumab (31YO63LBSN) ; Cetuximab (PQX0D8J21J) ; Biomarkers
    Language English
    Publishing date 2023-03-14
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000940
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer.

    Borcoman, Edith / Le Tourneau, Christophe

    Annals of translational medicine

    2020  Volume 8, Issue 23, Page(s) 1611

    Language English
    Publishing date 2020-06-17
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm-20-2656
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile Regression.

    Mboup, Bassirou / Le Tourneau, Christophe / Latouche, Aurélien

    JCO precision oncology

    2022  Volume 5, Page(s) 173–176

    Abstract: Purpose: Immunotherapy has been approved to treat many tumor types. However, one characteristic of this therapeutic class is that survival benefit is due to late immune response, which leads to a delayed treatment effect. Quantifying the benefit, if any, ...

    Abstract Purpose: Immunotherapy has been approved to treat many tumor types. However, one characteristic of this therapeutic class is that survival benefit is due to late immune response, which leads to a delayed treatment effect. Quantifying the benefit, if any, of such treatment, will thus require other metrics than the usual hazard ratio and different approaches have been proposed to quantify the long-term response of immunotherapy.
    Method: In this paper, we suggest to use quantile regression for survival data to quantify the long-term benefit of immunotherapy. Our motivation is that this approach is not trial-specific and provides clinically understandable results without specifying arbitrary time points or the necessity to reach median survival, as is the case with other methods. We use reconstructed data from published Kaplan-Meier curves to illustrate our method.
    Results: On average, patients from the immunotherapy group have 60% chance to survive 5.46 months (95% CI, 2.57 to 9.02) more than patients in the chemotherapy group.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Immunotherapy/methods ; Immunotherapy/mortality ; Immunotherapy/statistics & numerical data ; Kaplan-Meier Estimate ; Lung Neoplasms/drug therapy ; Regression Analysis
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2022-03-25
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.20.00164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Nanoparticle therapy for head and neck cancers.

    Hoffmann, Caroline / Shen, Colette / Le Tourneau, Christophe

    Current opinion in oncology

    2022  Volume 34, Issue 3, Page(s) 177–184

    Abstract: Purpose of review: The current review focuses on the therapeutic use of nanoparticles in head and neck cancer (HNC), highlighting nanoparticles at the most advanced clinical development stages.: Recent findings: Literature review covers the three ... ...

    Abstract Purpose of review: The current review focuses on the therapeutic use of nanoparticles in head and neck cancer (HNC), highlighting nanoparticles at the most advanced clinical development stages.
    Recent findings: Literature review covers the three main approaches for therapeutic use of nanoparticles in HNC: first, enhancing radiotherapy effect; second, performing targeted delivery of chemotherapy, immunotherapy, or genome editing molecules; third, photothermal therapy.
    Summary: Nanoparticles are spherical nanoscale objects that have application in cancer therapies. Nanoparticles have diverse and often composite structure composition to ensure their function, increase their bioavailability in tumor tissues, and decrease off-target effects, sometimes by means of activating internal or external stimuli. Hafnium oxide nanoparticles are being tested in phase I to III trials for radiotherapy enhancement. Nanoparticle-based delivery of paclitaxel, cisplatin, and of the immune activator CpG-A DNA is being evaluated in phase II trials. No nanoparticle is currently approved for HNC treatment.
    MeSH term(s) Cisplatin ; Head and Neck Neoplasms/drug therapy ; Humans ; Immunotherapy ; Nanoparticles
    Chemical Substances Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2022-03-09
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000828
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Drug development in the era of precision medicine in oncology-Clues beyond randomization.

    du Rusquec, Pauline / Filleron, Thomas / Le Tourneau, Christophe

    Chinese clinical oncology

    2021  Volume 10, Issue 3, Page(s) 23

    MeSH term(s) Drug Development ; Humans ; Medical Oncology ; Neoplasms/drug therapy ; Precision Medicine ; Random Allocation
    Language English
    Publishing date 2021-04-23
    Publishing country China
    Document type Journal Article
    ZDB-ID 2828547-5
    ISSN 2304-3873 ; 2304-3873
    ISSN (online) 2304-3873
    ISSN 2304-3873
    DOI 10.21037/cco-21-29
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?

    Ricci, Francesco / Le Tourneau, Christophe

    Chinese clinical oncology

    2019  Volume 8, Issue S1, Page(s) S14

    MeSH term(s) Albumins/pharmacology ; Albumins/therapeutic use ; Biomarkers/metabolism ; Breast Neoplasms/drug therapy ; Caveolin 1/pharmacology ; Caveolin 1/therapeutic use ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Female ; Humans ; Male ; Neoplasm Metastasis ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use
    Chemical Substances 130-nm albumin-bound paclitaxel ; Albumins ; Biomarkers ; Caveolin 1 ; Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2019-02-13
    Publishing country China
    Document type Editorial
    ZDB-ID 2828547-5
    ISSN 2304-3873 ; 2304-3865
    ISSN (online) 2304-3873
    ISSN 2304-3865
    DOI 10.21037/cco.2019.01.08
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

    Borcoman, Edith / Marret, Gregoire / Le Tourneau, Christophe

    Cancers

    2021  Volume 13, Issue 11

    Abstract: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in combination with platinum-based chemotherapy has been for the decade standard of care for the treatment of head and neck squamous cell carcinomas (HNSCC) patients ... ...

    Abstract Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in combination with platinum-based chemotherapy has been for the decade standard of care for the treatment of head and neck squamous cell carcinomas (HNSCC) patients in the first-line recurrent and/or metastatic setting. The KEYNOTE-048 trial published last year established a new paradigm in this setting with the demonstration that immunotherapy should be given either alone or in combination with chemotherapy. Indeed, pembrolizumab, an antiprogrammed cell death 1 (PD-1) immune checkpoint inhibitor, improved overall survival as compared to the EXTREME regimen in patients expressing PD-L1 in the tumor microenvironment, which represents a large majority of the patient population. In this review, we will decipher this important change of paradigm in the first-line treatment of recurrent and/or metastatic HNSCC, and discuss associated challenges.
    Language English
    Publishing date 2021-05-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13112573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top